FindTrial
Sign In

Minimal residual disease assessed by multi-parameter flow cytometry for leukemia stem cells in patients with acute myeloid leukaemia who underwent allogeneic stem cell transplantation

Minimal residual disease assessed by multi-parameter flow cytometry for leukemia stem cells in patients with acute myeloid leukaemia who underwent allogeneic stem cell transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016458
Enrollment
Unknown
Registered
2018-06-02
Start date
2018-06-30
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute leukemia

Interventions

Case series:Post allogeneic stem cell transplantation

Sponsors

Peking University People's Hospital & Peking University Institute of Hematology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) Allogeneic stem cell transplantation candidates with acute myeloid leukemia. Donor selection was performed as the follows: HLA-matched sibling donor was the first choice for allo-transplantation. If an HLA-matched sibling donor was unavailable, subjects without a suitable closely HLA-matched unrelated donor (URD; >8 of 10 matching HLA-A, B, C, DR, and DQloci and >5 of 6 matching HLA-A, B, and DR loci) after 2 cycles of consolidation were eligible for HLA-haplotype transplantation; 2) Between 6 and 60 years-old; 3) To be able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1) Contraindications of transplantation; 2) Subjects who cannot comply with the study.

Design outcomes

Primary

MeasureTime frame
Relapse;—

Countries

China

Contacts

Public ContactChang Yingjun

Peking University People's Hospital & Peking University Institute of Hematology

rmcyj@bjmu.edu.cn+86 13520536738

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026